S
Strata Oncology
Precision oncology company dedicated to transforming cancer care
About Strata Oncology
Strata Oncology is a pioneering startup in the field of precision oncology, which is a specialized area of medicine that uses genetic information about a patient's tumor to help doctors decide which treatments will work best. The company's primary offering is a first-of-its-kind molecular profiling test that guides treatment selection for immunotherapy and beyond. This test is covered by Medicare, making it accessible to a broad range of patients.
Strata Oncology serves a diverse clientele, including healthcare providers, researchers, and patients. The company's fast turnaround time, comprehensive genomic information, and expert pathologist assessment help healthcare providers make informed treatment decisions for their advanced cancer patients.
The company operates in the healthcare market, specifically in the cancer treatment sector. Its business model revolves around providing personalized cancer treatment solutions based on molecular profiling. Strata Oncology generates revenue by offering its molecular profiling test and related services to healthcare providers and patients.
In addition to its current offerings, the company is also actively involved in research and development to advance new precision treatment hypotheses. This includes the development of gene expression-based oncology therapeutics and proprietary treatment selection algorithms, which are expected to bring new treatment options to cancer patients.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Ann Arbor, United States
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 66.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Nov 2024 | $6.2M | — | Undisclosed | ↗ |
| SERIES COther financing | Jul 2021 | $90M | $360M | Baird Capital · Arboretum Ventures · Renaissance Venture Capital Fund · Cormorant Asset Management | — |
Growth signals
Latest recorded traffic for Strata Oncology is 2.3K monthly website visits, up 9.5% over the last three months. Strata Oncology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Robert W. Baird & Co.
Arboretum Ventures
Baird Capital
ELab Ventures- PVPfizer Ventures
Series B and later6 investors entered at this stage
Wellington Management
Renaissance Venture Capital Fund
Cormorant Asset Management
Merck Global Health Innovation Fund
Highside Capital Management
Monashee Investment Management
Other known investors1 additional known investor
University of Michigan
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Strata Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Strata Oncology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.